Compare AbCellera Biologics Inc (ABCL) vs Beyond Meat Inc (BYND) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Beyond Meat Inc — how do they compare? AbCellera Biologics Inc trades at $7.18 (market cap $2.35B), while Beyond Meat Inc trades at $0.67 (market cap $366.00M). The key difference: AbCellera Biologics Inc is far larger — about 6.4× Beyond Meat Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Beyond Meat Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | BYND | |
|---|---|---|
Market Cap | $2.35B | $366.00M |
Sector | Health | Consumer Staples |
52-Week High | $8.12 | $4.28 |
52-Week Low | $2.78 | $0.52 |
Enterprise Value | $1.99B | $675.99M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
BYND trades at $0.7102, down slightly by 0.01% on the day, with a neutral technical signal and bearish moving averages. The company reported a net income of $178.01M in 2025, a significant turnaround from prior losses, though revenue declined to $275.50M. Recent news highlights expansion of Beyond Steak Filet into major retailers like Meijer and Wegmans, alongside new product launches such as Beyond Immerse protein drinks, aiming to revive growth amid challenging sales trends.
The outlook remains cautious due to persistent revenue declines and negative cash flow from operations, offset by strong profitability margins and positive net income. Risks include execution challenges in new product categories and high sell-side analyst skepticism, with 57.14% recommending sell. Investment opportunity hinges on successful turnaround efforts driving sustainable top-line growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Beyond Meat Inc
Beyond Meat is a provider of plant-based meats, such as burgers, sausage, ground beef, and chicken. Unlike other vegetarian products, Beyond Meat seeks to replicate the look, cook, and taste of meat, is targeted to omnivores and vegetarians alike, and is sold in the meat case. The products are widely available across the U.S. and Canada and in 83 additional countries as well. International revenue represented 31% of 2021 sales. The firm's products are available in retail stores and the food-service channel. In 2019, before the pandemic struck, sales were evenly split between these two channels, although mix stood at 70% retail/30% food service in 2021. We think the recovery from the crisis and new deals with McDonald's and Yum Brands will return food-service sales to nearly 50% in time.
Read more on BYND →
